Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
Novel suite of computer algorithms can accurately predict behavior of gut microbiome

Novel suite of computer algorithms can accurately predict behavior of gut microbiome

A team of investigators from Brigham and Women's Hospital and the University of Massachusetts have developed a suite of computer algorithms that can accurately predict the behavior of the microbiome - the vast collection of microbes living on and inside the human body. [More]
Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut. [More]
Transplanted human stool may offer treatment hope for ulcerative colitis patients

Transplanted human stool may offer treatment hope for ulcerative colitis patients

Patients with ulcerative colitis (UC) may improve their symptoms with a transplantation of healthy stool from donors, according to Australian researchers. The findings were presented by Dr Sudarchan Paramsothy MD, a gastroenterologist from the University of New South Wales, Australia at the Digestive Disease Week conference in San Diego, California between the 21st to 24th May. [More]
New frozen faecal bank increases chances of curing a chronic health condition

New frozen faecal bank increases chances of curing a chronic health condition

A new frozen faecal bank that could save hundreds of lives and dramatically improve the quality of life of many more has been established at a Portsmouth hospital. [More]
Ramizol drug shows promise in treatment of Clostridium difficile infections

Ramizol drug shows promise in treatment of Clostridium difficile infections

A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action. [More]
Potential vaccine that resembles sugar structures may help fight against gut bacterium C. difficile

Potential vaccine that resembles sugar structures may help fight against gut bacterium C. difficile

A vaccine against one of the most dangerous hospital germs may soon be available. Scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universität Berlin have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile. [More]
UAB hospital leads the way in improving antibiotic use

UAB hospital leads the way in improving antibiotic use

One of today's urgent health threats is antibiotic resistance, caused by inappropriate prescription and use of antibiotics, and — according to the Centers for Disease Control and Prevention — approximately 50 percent of all antibiotics prescribed in the United States are unnecessary or inappropriate, with many of them prescribed in inpatient settings. [More]
Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

An estimated 30 percent of outpatient oral antibiotic prescriptions in the U.S. in 2010-2011 may have been inappropriate, findings that support the need for establishing a goal for outpatient antibiotic stewardship, according to a study appearing in the May 3 issue of JAMA. [More]
UGA researcher works to advance effective treatment for infectious mononucleosis

UGA researcher works to advance effective treatment for infectious mononucleosis

The University of Georgia's Mark Ebell wasn't impressed with research on infectious mononucleosis when he wrote his first published review on it back in the 1990s. He still isn't—a subject he discusses in the April issue of the Journal of the American Medical Association. [More]
Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

The rise of antibiotic resistant bacterial pathogens is an increasingly global threat to public health. In the United States alone antibiotic resistant bacterial pathogens kill thousands every year. [More]
UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy. [More]
Novel antibiotics to overcome antibacterial resistance

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam. [More]
Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Communities of viruses can be transferred during fecal transplants, according to a study published this week in mBio, an online open-access journal of the American Society for Microbiology. Fortunately for patients who use this procedure, the viruses found to be transmitted in this study appear to be harmless to humans. [More]
Changing one atom in InsP6 inhibitor can increase its ability to neutralize toxins in the gut

Changing one atom in InsP6 inhibitor can increase its ability to neutralize toxins in the gut

Infections with bacterium Clostridium difficile have rapidly become a significant medical problem in hospitals and long-term care facilities. The bacteria cause diarrhea and life-threatening inflammation of the colon by producing toxins that kill the endothelial cells that form the lining of the gut. [More]
Valley Hospital, Holy Name Medical Center collaborate to defeat C. difficile

Valley Hospital, Holy Name Medical Center collaborate to defeat C. difficile

The Valley Hospital in Ridgewood, NJ, and Holy Name Medical Center in Teaneck, NJ, are collaborating to defeat a common foe: a dangerous drug-resistant bacterium called Clostridium difficile, or C. difficile. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Discovery takes researchers one step closer to preventing C. diff

Discovery takes researchers one step closer to preventing C. diff

Exposure to specific antibiotics is linked to the development of certain strains of antibiotic-resistant C. difficile, one of the fastest growing bacteria superbugs, according to a new study published by Stuart Johnson, MD, of Loyola University Health System, Loyola University Chicago Stritch School of Medicine and the Hines VA Medical Hospital. [More]
CosmosID announces $6M in Series B funding round

CosmosID announces $6M in Series B funding round

CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding. [More]
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection. [More]

Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health care facility. C-diff can cause a variety of symptoms, including potentially deadly diarrhea. A recent national report shows some progress in reducing C-diff infections; however, more work remains. [More]
Advertisement
Advertisement